Ligand Pharmaceuticals Inc (LGND) KPIs and segments
Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –
KPIs & segments
Operating metrics and segments that drive Ligand Pharmaceuticals's business
Ligand Pharmaceuticals's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Royalties($M) | 70.3 | 48.0 | 43.0 | 50.5 | 46.6 | 36.4 | 27.5 | 34.8 | 31.7 | 23.2 | 19.1 | 22.5 | |
Revenue from intangible royalty assets($M) | 47.4 | 37.4 | 32.9 | 40.7 | 40.2 | 30.1 | 21.6 | 27.8 | 26.6 | 22.6 | 18.4 | 22.5 | |
Income from financial royalty assets($M) | 22.9 | 10.7 | 10.0 | 9.83 | 6.43 | 6.31 | 5.90 | 6.99 | 5.16 | 0.56 | 0.74 | 0.02 | |
Filspari($M) | 16.8 | 13.6 | 11.3 | 11.0 | 9.08 | 6.58 | 5.30 | 4.78 | 3.21 | 2.42 | 1.77 | 0.95 | |
Kyprolis($M) | 10.5 | 7.04 | 6.74 | 11.6 | 8.80 | 4.72 | 11.6 | 9.00 | 6.63 | ||||
Captisol($M) | 7.95 | 7.98 | 8.65 | 7.79 | 10.7 | 8.29 | 13.5 | 7.92 | 6.26 | 7.50 | 9.21 | 3.92 | |
Ojemda($M) | 7.00 | 0 | |||||||||||
Qarziba($M) | 5.95 | 6.15 | 6.30 | 6.44 | 5.98 | 5.89 | 5.44 | 6.49 | 4.63 | 0 | 0 | ||
Capvaxive($M) | 3.80 | 2.32 | 1.97 | 3.72 | 3.21 | 2.25 | 0.89 | 0.19 | 0.44 | ||||
Ohtuvayre($M) | 3.70 | 4.14 | 2.99 | 3.55 | 2.72 | 2.08 | 1.41 | 0.72 | 0.11 | ||||
Vabysmo($M) | 3.58 | 0 | |||||||||||
Rylaze($M) | 3.53 | 3.20 | 3.22 | 3.56 | 2.86 | 3.12 | 3.89 | 3.23 | 2.95 | ||||
Ohtuvayre inventors($M) | 3.25 | 3.29 | 3.05 | 0 | 0 | 0 | |||||||
Evomela($M) | 1.89 | 1.47 | 1.98 | 1.75 | 2.73 | 1.40 | |||||||
Miplyffa($M) | 1.68 | 0 | |||||||||||
Other($M) | 1.40 | 1.23 | 0.68 | 3.39 | 0.45 | 0.43 | 0.46 | 0.50 | 0.53 | 0.56 | 0.74 | 1.50 | |
Teriparatide injection($M) | 1.33 | 1.47 | 1.32 | 2.63 | 2.30 | 1.19 | 2.38 | 2.10 | 2.04 | ||||
Vaxneuvance($M) | 1.07 | 1.35 | 1.61 | 1.44 | 2.04 | 2.64 | 1.29 | 1.22 | 1.47 | 1.11 | 1.39 | 1.07 | |
Contract revenue and income($M) | 0.52 | 7.68 | 0.11 | 1.34 | 58.2 | 2.94 | 4.38 | 0.09 | 13.8 | 10.9 | 2.67 | 1.69 | |
Contract revenue($M) | 0.34 | 2.68 | 0.11 | 60.4 | 0.13 | 1.93 | 4.38 | 2.03 | 13.8 | 0.67 | |||
Income($M) | 0.18 | 5 | 5 | 1.02 | 0 | 0 | 0 | 1.94 | |||||
Income from Pelthos Transaction($M) | 0 | 0 | 53.1 | 0 | 0 | ||||||||
Earlier reporting (last reported 2025)3 | |||||||||||||
Earlier reporting (last reported 2026)1 | |||||||||||||
Earlier reporting (last reported 2026)1 | |||||||||||||
23 metrics have no data in the last 12 quarters — .
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-10-30.
See a number that looks wrong?